Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results from a rival Novo Nordisk (NVO) drug.
Novo Nordisk shares drop more than 4% on disappointing obesity pill data
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations.
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some psychiatric side effects, new data show.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
BioSpace2d
Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
studyfinds9d
13% weight loss in 3 months! Obesity pill amycretin shows promise of replacing Ozempic injections
A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...
Roche shares knocked by concern over side effects in obesity pill trial
Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...
devdiscourse20h
Novo Nordisk's Obesity Pill Falls Short in Phase 2a Trial
Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing
Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...
BioSpace9d
Novo’s Obesity Pill Yields ‘Remarkable’ 13% Weight Loss, Investigators Say
On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...
Nasdaq8d
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in ...